Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Medpace stock | $188.38

Learn how to easily invest in Medpace stock.

Medpace Holdings Inc is a diagnostics & research business based in the US. Medpace shares (MEDP) are listed on the NASDAQ and all prices are listed in US Dollars. Medpace employs 4,100 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Medpace

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MEDP – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Medpace stock price (NASDAQ: MEDP)

Use our graph to track the performance of MEDP stocks over time.

Medpace shares at a glance

Information last updated 2021-10-24.
Latest market close$188.38
52-week range$105.48 - $199.04
50-day moving average $188.43
200-day moving average $178.89
Wall St. target price$170.50
PE ratio 40.319
Dividend yield N/A (0%)
Earnings per share (TTM) $4.64

Buy Medpace shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Medpace stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Medpace price performance over time

Historical closes compared with the close of $188.38 from 2021-10-25

1 week (2021-10-19) 1.46%
1 month (2021-09-24) -4.96%
3 months (2021-07-26) 3.83%
6 months (2021-04-26) -3.05%
1 year (2020-10-23) 61.64%
2 years (2019-10-25) 149.94%
3 years (2018-10-25) 276.53%
5 years (2016-10-25) 519.67%

Is Medpace under- or over-valued?

Valuing Medpace stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Medpace's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Medpace's P/E ratio

Medpace's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 40x. In other words, Medpace shares trade at around 40x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Medpace's PEG ratio

Medpace's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.97. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Medpace's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Medpace's EBITDA

Medpace's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $212.2 million.

The EBITDA is a measure of a Medpace's overall financial performance and is widely used to measure a its profitability.

Medpace financials

Revenue TTM $1 billion
Operating margin TTM 18.62%
Gross profit TTM $571.5 million
Return on assets TTM 8.89%
Return on equity TTM 22.08%
Profit margin 17.07%
Book value $23.91
Market capitalisation $6.7 billion

TTM: trailing 12 months

Shorting Medpace shares

There are currently 896,880 Medpace shares held short by investors – that's known as Medpace's "short interest". This figure is 1.9% up from 879,885 last month.

There are a few different ways that this level of interest in shorting Medpace shares can be evaluated.

Medpace's "short interest ratio" (SIR)

Medpace's "short interest ratio" (SIR) is the quantity of Medpace shares currently shorted divided by the average quantity of Medpace shares traded daily (recently around 217162.22760291). Medpace's SIR currently stands at 4.13. In other words for every 100,000 Medpace shares traded daily on the market, roughly 4130 shares are currently held short.

However Medpace's short interest can also be evaluated against the total number of Medpace shares, or, against the total number of tradable Medpace shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Medpace's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Medpace shares in existence, roughly 30 shares are currently held short) or 0.0362% of the tradable shares (for every 100,000 tradable Medpace shares, roughly 36 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Medpace.

Find out more about how you can short Medpace stock.

Medpace share dividends

We're not expecting Medpace to pay a dividend over the next 12 months.

Medpace share price volatility

Over the last 12 months, Medpace's shares have ranged in value from as little as $105.48 up to $199.039. A popular way to gauge a stock's volatility is its "beta".

MEDP.US volatility(beta: 1.3)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Medpace's is 1.2963. This would suggest that Medpace's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Medpace overview

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

Frequently asked questions

What percentage of Medpace is owned by insiders or institutions?
Currently 20.31% of Medpace shares are held by insiders and 79.251% by institutions.
How many people work for Medpace?
Latest data suggests 4,100 work at Medpace.
When does the fiscal year end for Medpace?
Medpace's fiscal year ends in December.
Where is Medpace based?
Medpace's address is: 5375 Medpace Way, Cincinnati, OH, United States, 45227
What is Medpace's ISIN number?
Medpace's international securities identification number is: US58506Q1094
What is Medpace's CUSIP number?
Medpace's Committee on Uniform Securities Identification Procedures number is: 58506Q109

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site